Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia

Description

This study is being done to observe the effects of treatment from a device called the Bioboosti which utilizes pulsed electromagnetic waves on its ability to improve blood flow to the heart tissue in individuals with coronary artery disease (CAD).

Conditions

Coronary Artery Disease, Myocardial Infarction

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is being done to observe the effects of treatment from a device called the Bioboosti which utilizes pulsed electromagnetic waves on its ability to improve blood flow to the heart tissue in individuals with coronary artery disease (CAD).

Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia

Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia

Condition
Coronary Artery Disease
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥ 18 years old.
  • * Known cardiac ischemia, who are non revascularizable, or have not and will not be undergo coronary intervention for the duration of their participation in the study.
  • * Evidence of ischemia from previous clinical tests (echo, nuclear, standard ECG from past 6 months).
  • * Left Ventricular Ejection fraction \> 40% by echo (evaluated last 3 months).
  • * Able to complete a cardiopulmonary exercise test without significant non cardiac limitations, primarily orthopedic.
  • * On guideline directed optimal therapy for stable ischemia.
  • * Anemia (\< 7 mg/dl).
  • * Low potassium (\< 3 mmol/L).
  • * Creatinine (\> 5.0 mg/dl or \< 0.6 mg/dl).
  • * Unable to exercise due primarily to orthopedic limitation.
  • * Severe lung disease.
  • * Morbid obesity (BMI \> 42).
  • * Pregnant.
  • * Breast feeding.
  • * Significant arrhythmia (ventricular tachycardia, ventricular fibrillation, frequent premature ventricular contractions (PVCs), persistent atrial fibrillation, or 2nd or 3rd degree atrioventricular (AV) block).
  • * Seizures.
  • * Unstable angina.
  • * Coronary spasm.
  • * Recent myocardial infarction (\< 90 days).
  • * Recent percutaneous coronary intervention (\<90 days).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Courtney Wheatley-Guy, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Bruce Johnson, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2025-11